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To the Editor:
Enthusiasm and use of transcatheter
aortic valve implantation (TAVI) have
grown exponentially since the first
TAVI procedure was performed a de-
cade ago. Critics of this relatively
novel technique, however, argue that
clinical practice has far outpaced ro-
bust clinical evidence. The recent
summary by Agnihotri1 provides
a broad overview of the recent consen-
sus statement approved by a dozen
professional societies, including the
American Association for Thoracic
Surgery. Agnihotri1 correctly empha-
sizes the subjectivity of the patient se-
lection process for TAVI and a number
of postprocedural complications such
as stroke, requirement for permanentFIGURE 1. Spectrum of patients with severe aortic s
aortic valve implantation.
The Journalpacemaker, vascular injury, and se-
vere aortic regurgitation, all of which
are significantly more likely to occur
than after conventional surgical aortic
valve replacement (AVR). Agnihotri1
also stated, ‘‘There is limited informa-
tion regarding durability beyond 5
years in registry data.’’ One should
also point out there are no published
comparative data between TAVI and
surgical AVR beyond 5 years in the
current literature.
Fromanevidence-basedperspective,
level I evidencehasonlybeenpresented
from 2 randomized controlled trials.
The better known of these, the PART-
NER (Placement of Aortic Transcath-
eter Valve) trial financed by Edwards
Lifesciences (Irvine, Calif), involved
patients who were either deemed to be
at ‘‘high surgical risk’’ (cohort A) or
‘‘inoperable’’ (cohort B).2,3 Recently,
Van Brabandt and colleagues4 high-
lighted the significant ethical, scientific,
and industry-related challenges to the
PARTNER trial related to publication
bias, lack of data transparency, unbal-
anced patient characteristics, and in-
completely declared conflicts of
interest.4 The lesser known STAC-
CATO trial, whichwas not cited byAg-
nihotri1 or the consensus statement,
included patients who were considered
to have ‘‘low surgical risk.’’ This trial
was prematurely terminated by a data
safetymonitoring board after unexpect-
edly poor results for patients in the
TAVI arm.5 The chief investigator of
the STACCATO trial stated that TAVI
should not be considered in patients
who are at a low surgical risk because
of the excellent and established out-
comes offered by surgical AVR.tenosis according to surgical risk for conventional aor
of Thoracic and Cardiovascular SurgeIn summary, patients with severe
aortic stenosis should be considered
in three subgroups, according to their
surgical risk with conventional AVR,
as illustrated in Figure 1. Results
from randomized, controlled trials
suggest that ‘‘inoperable’’ patients
may benefit from TAVI in terms of
mortality and symptomatic outcomes,
although at the cost of increased
stroke risk. The evidence for ‘‘high
surgical risk’’ patients is limited by
short-term follow-up, and existing
data suggest a higher risk of stroke
or transient ischemic attack than that
associated with conventional AVR
without any significant all-cause mor-
tality benefit. With respect to ‘‘low
surgical risk’’ patients, the STAC-
CATO trial has shown that TAVI
should not be offered to these patients
in the current clinical setting. Finally,
there is a fourth recognized subgroup
of patients who are considered to be
at too high a risk for any form of inter-
ventional treatment.2,3
In the future, the development of
novel devices should also be comple-
mented by the development of stan-
dardized, stringent patient selection
processes to allow meaningful com-
parison of outcomes between institu-
tions. On the basis of the available
evidence, the use of TAVI for eligible
surgical candidates should only be
considered within clinical trials or
registries.6
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ARTERY?
To the Editor:
We read with interest the recent
report by Myers and associates.1 The616 The Journal of Thoracic and Cauthors presented their experience
and outcomes of extensive endarterec-
tomy and reconstruction of the left an-
terior descending artery (LAD) and
compared 2 different reconstruction
methods: vein patch reconstruction
with the left internal thoracic artery
(LITA) and LITA onlay patch graft-
ing. The authors showed that the early
results were excellent and that the re-
construction method did not have
a significant effect on long-term sur-
vival in this challenging group of
patients. However, we have several
concerns about, and comments on,
this retrospective review.
First, the actuarial 10-year survival
in both groups was less than 50%,
which seems lower than expected
compared with the overall long-term
results of off-pump coronary artery
bypass surgery.2 The causes of death
were not clearly documented in their
report. Because patients who required
extensive coronary endarterectomy
might have had severe coronary artery
disease, it is important to know the
early and late causes of deaths. Never-
theless, we also recently the published
long-term results of long segmental
reconstruction of the LAD using the
LITA in 112 patients.3 Of these pa-
tients, 37 underwent endarterectomy,
and their 10-year survival rate was ap-
proximately 75%, comparable with
the results of the previous report for
patients who underwent conventional
coronary artery bypass surgery.2 Al-
though we have no data on vein patch
reconstruction with the LITA, we be-
lieve that onlay patch reconstruction
of the LAD using the LITA is quite
important to achieve a favorable out-
come in the treatment of patients
with diffusely diseased coronary
arteries. In patients with LITA onlay
patch grafts, the wall of the LITA
forms a new coronary lumen, and the
atheromatous plaques are almost
totally excluded from the LAD lumen.
Intimal hyperplasia rarely occurs in
a LAD reconstructed with the LITA,
although vein graft disease has been
proved to progress with time.4ardiovascular Surgery c February 2013An optimal endarterectomy tech-
nique and appropriate postoperative
anticoagulation strategy are vital to
achieve excellent long-term outcomes
in these group of patients. We rou-
tinely tack the divided intima of the
distal LAD with 8-0 polypropylene
sutures. We believe this maneuver,
coupled with postoperative anticoagu-
lation, is important to prevent obstruc-
tion of distal run-off by residual
intima, where thrombosis readily
occurs. Our current anticoagulation
strategy is as follows. First, low-
molecular-weight heparin (5000 U/d)
is initiated, after confirmation of he-
mostasis in the intensive care unit.
Second, low-dose aspirin, clopidog-
rel, and warfarin (with a target inter-
national normalized ratio of 2.0) are
started after the patients have resumed
oral intake. Third, low-molecular-
weight heparin is discontinued after
warfarin is effective. Finally, clopi-
dogrel is continued for 1 month and
warfarin for 6 months. We reported
immediate postoperative angio-
graphic results with a 97% LITA
patency rate (34/35) in patients under-
going long onlay patch reconstruction
of the LAD with endarterectomy.
Their long-term (approximately 10
years) patency rate was 100% (7/7).3
In our recent study, we also reported
a 94% immediate postoperative
LITA patency in 134 patients using
the same technique.5 A similar sur-
vival rate between vein patch
reconstruction with the LITA and
LITA onlay patch grafting does not
always mean a similar patency rate.
Reconstruction of the LAD with
a vein patch can result in a lower pa-
tency rate. We all know that postoper-
ative angiography is rarely performed
unless patients have significant symp-
toms. However, it is important to
know the fate of these 2 different
reconstruction techniques late after
surgery. We wonder whether any late
angiographic data were available for
these 2 groups of patients. We con-
gratulate the authors for their effort
in tackling this difficult group of
